Literature DB >> 30885992

Adaptation to HIF1α Deletion in Hypoxic Cancer Cells by Upregulation of GLUT14 and Creatine Metabolism.

Alessandro Valli1,2, Matteo Morotti3, Christos E Zois3, Patrick K Albers4, Tomoyoshi Soga5, Katharina Feldinger3, Roman Fischer2, Martin Frejno2, Alan McIntyre3, Esther Bridges3, Syed Haider3, Francesca M Buffa3, Dilair Baban4, Miguel Rodriguez6,7, Oscar Yanes6,7, Hannah J Whittington8, Hannah A Lake8, Sevasti Zervou8, Craig A Lygate8, Benedikt M Kessler2, Adrian L Harris3.   

Abstract

Hypoxia-inducible factor 1α is a key regulator of the hypoxia response in normal and cancer tissues. It is well recognized to regulate glycolysis and is a target for therapy. However, how tumor cells adapt to grow in the absence of HIF1α is poorly understood and an important concept to understand for developing targeted therapies is the flexibility of the metabolic response to hypoxia via alternative pathways. We analyzed pathways that allow cells to survive hypoxic stress in the absence of HIF1α, using the HCT116 colon cancer cell line with deleted HIF1α versus control. Spheroids were used to provide a 3D model of metabolic gradients. We conducted a metabolomic, transcriptomic, and proteomic analysis and integrated the results. These showed surprisingly that in three-dimensional growth, a key regulatory step of glycolysis is Aldolase A rather than phosphofructokinase. Furthermore, glucose uptake could be maintained in hypoxia through upregulation of GLUT14, not previously recognized in this role. Finally, there was a marked adaptation and change of phosphocreatine energy pathways, which made the cells susceptible to inhibition of creatine metabolism in hypoxic conditions. Overall, our studies show a complex adaptation to hypoxia that can bypass HIF1α, but it is targetable and it provides new insight into the key metabolic pathways involved in cancer growth. IMPLICATIONS: Under hypoxia and HIF1 blockade, cancer cells adapt their energy metabolism via upregulation of the GLUT14 glucose transporter and creatine metabolism providing new avenues for drug targeting. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30885992     DOI: 10.1158/1541-7786.MCR-18-0315

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  6 in total

1.  Rac1 repression reverses chemoresistance by targeting tumor metabolism.

Authors:  Shanmugasundaram Ganapathy-Kanniappan
Journal:  Cancer Biol Ther       Date:  2020-08-31       Impact factor: 4.742

2.  SLC6A8-mediated intracellular creatine accumulation enhances hypoxic breast cancer cell survival via ameliorating oxidative stress.

Authors:  Qiao Li; Manran Liu; Yan Sun; Ting Jin; Pengpeng Zhu; Xueying Wan; Yixuan Hou; Gang Tu
Journal:  J Exp Clin Cancer Res       Date:  2021-05-14

3.  Malignancy Grade-Dependent Mapping of Metabolic Landscapes in Human Urothelial Bladder Cancer: Identification of Novel, Diagnostic, and Druggable Biomarkers.

Authors:  Aikaterini Iliou; Aristeidis Panagiotakis; Aikaterini F Giannopoulou; Dimitra Benaki; Mariangela Kosmopoulou; Athanassios D Velentzas; Ourania E Tsitsilonis; Issidora S Papassideri; Gerassimos E Voutsinas; Eumorphia G Konstantakou; Evagelos Gikas; Emmanuel Mikros; Dimitrios J Stravopodis
Journal:  Int J Mol Sci       Date:  2020-03-10       Impact factor: 5.923

4.  ANKRD22, a novel tumor microenvironment-induced mitochondrial protein promotes metabolic reprogramming of colorectal cancer cells.

Authors:  Tianhui Pan; Jingwen Liu; Song Xu; Qiao Yu; Hongping Wang; Hongxiang Sun; Jia Wu; Yue Zhu; Jianwei Zhou; Yongliang Zhu
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

Review 5.  Gut Microbiota and Colorectal Cancer Development: A Closer Look to the Adenoma-Carcinoma Sequence.

Authors:  Marco Vacante; Roberto Ciuni; Francesco Basile; Antonio Biondi
Journal:  Biomedicines       Date:  2020-11-10

Review 6.  Metabolic Reprogramming of Thyroid Cancer Cells and Crosstalk in Their Microenvironment.

Authors:  Lisha Bao; Tong Xu; Xixuan Lu; Ping Huang; Zongfu Pan; Minghua Ge
Journal:  Front Oncol       Date:  2021-12-02       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.